A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients

Publisher： Karger

E-ISSN： 1421-9794|58|5|411-418

ISSN： 0009-3157

Source： Chemotherapy, Vol.58, Iss.5, 2013-01, pp. : 411-418

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer

By  

Chemotherapy, Vol. 54, Iss. 3, 2008-06 ,pp. : 228-235

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-07 ,pp. : 79-84

Karger

Access to resources Recommend Favorite

Effect of S-1 Adjuvant Chemotherapy on Survival following Recurrence and Efficacy of First-Line Treatment in Recurrent Gastric Cancer

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 436-443

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Modified FOLFOX6 for Treatment of Metastatic or Locally Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 54, Iss. 5, 2008-09 ,pp. : 395-403

Karger

Access to resources Recommend Favorite

Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer

By  

Chemotherapy, Vol. 56, Iss. 2, 2010-03 ,pp. : 94-100

Karger

Access to resources Recommend Favorite